Nucana (NCNA) has released an update. NuCana’s recent Phase 1b/2 study results reveal promising efficacy of its new drug NUC-3373 in combination with pembrolizumab and docetaxel for patients with ...

Full details can be found in the publication: Link Professor David Harrison, NuCana’s Head of Translational Medicine, stated: “We previously presented data on NUC-3373’s ability to elicit the release ...

NuCana (NASDAQ:NCNA) just reported results for the second quarter of 2024. NuCana reported earnings per share of -15 cents. This was above the analyst estimate for EPS of -$2.35. The company did ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Full details can be found in the publication: Link Professor David Harrison, NuCana’s Head of Translational Medicine, stated: “We previously presented data on NUC-3373’s ability to elicit ...

EDINBURGH, United Kingdom, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in ...

Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdom, Nov. 11 ...

Following treatment with NUC-3373 plus docetaxel, the patient achieved Stable Disease for 7 months. Professor David Harrison, NuCana's Head of Translational Medicine, stated: "We previously presented ...

EDINBURGH, United Kingdom, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that initial data from the ongoing Phase 1b/2 modular study (NuTide:303) investigating NUC-3373 in ...